Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 3:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: HPMC Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects

NCT03135509
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CC-220
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 19, 2026, 3:35 PM EDT
Not listed Phase 1 Interventional

Study of MTB-9655, an Inhibitor of ACSS2, in Patients With Advanced Solid Tumors

NCT04990739
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
MTB-9655
Drug
Lead sponsor
MetaboMed Inc
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 19, 2026, 3:35 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Riboflavin/Dextran or Riboflavin/Methylcellulose

NCT04897503
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
Riboflavin
Drug
Lead sponsor
Cornea and Laser Eye Institute
Other
Eligibility
12 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 19, 2026, 3:35 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Visual Surround Suppression and Perceptual Expectation Under Psilocybin

NCT04424225
View directory record Official record
Conditions
Perception Disturbance, Visual Suppression, Psychedelic Experiences
Interventions
Psilocybin, Niacin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
25 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 19, 2026, 3:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Performance of the ID-Cap System, an Ingestion Event Marker, in the Clinical Setting as an Aid to Measure Medication Adherence

NCT03653897
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ID-Capsule- Active, Wearable Sensor
Device
Lead sponsor
EtectRX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Oct 19, 2026, 3:35 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD

NCT05686044
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Buntanetap/Posiphen, Placebo
Drug
Lead sponsor
Annovis Bio Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
54
States / cities
Gilbert, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 19, 2026, 3:35 PM EDT
Withdrawn Phase 2 Interventional

Efficacy Study of Ketorolac and HPMC to Treat Dry Eye

NCT03693183
View directory record Official record
Conditions
Dry Eye
Interventions
Ketorolac/HPMC, HPMC, Vehicle
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 19, 2026, 3:35 PM EDT
Completed Phase 3 Interventional Results available

Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil

NCT03399604
View directory record Official record
Conditions
Primary Pulmonary Hypertension
Interventions
LIQ861 Inhaled Treprostinil
Drug
Lead sponsor
Liquidia Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
38
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 19, 2026, 3:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pharmacokinetics of Essential Oils in Different Capsules

NCT07581522
View directory record Official record
Conditions
Healthy, Health, Subjective
Interventions
Frankinscense Essential Oil Capsule, Lemon Essential Oil Capsule, Wild Orange Essential Oil Capsule
Other
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 35 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 19, 2026, 3:35 PM EDT
Completed Phase 1 Interventional

An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor

NCT01231568
View directory record Official record
Conditions
Cancer
Interventions
Regimen A, Regimen B, Regimen C, Regimen D
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Scottsdale, Arizona • Detroit, Michigan • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 19, 2026, 3:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Evaluation of Psilocybin's Effect on Cardiac Repolarization and the Effect of Food on Psilocybin's Pharmacokinetics

NCT05478278
View directory record Official record
Conditions
QTc Interval, Pharmacokinetics
Interventions
Psilocybin, Moxifloxacin, Micro-Crystalline Cellulose
Drug
Lead sponsor
Usona Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 19, 2026, 3:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects

NCT03457727
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Danirixin, Omeprazole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 19, 2026, 3:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Development of Adherence Biomarkers for Multiple Microbicide and Multipurpose Prevention Technology (MPT) Dosage Forms

NCT02569697
View directory record Official record
Conditions
HIV
Interventions
HEC Placebo gel, Placebo Intravaginal Ring, Placebo Vaginal Film, Placebo Vaginal Insert
Other
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 2, 2016 · Synced Oct 19, 2026, 3:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Hemp 15 mg & 50 mg Capsule Absorption

NCT05076890
View directory record Official record
Conditions
Absorption; Chemicals
Interventions
15 mg/g Full Spectrum Hemp Extract, 50 mg/g Full Spectrum Hemp Extract
Dietary Supplement
Lead sponsor
Gaia Herbs Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Oakwood, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 19, 2026, 3:35 PM EDT
Completed Phase 2 Interventional Results available

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

NCT01336634
View directory record Official record
Conditions
Cancer
Interventions
Dabrafenib, Trametinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
15
States / cities
Los Angeles, California • Orange, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 19, 2026, 3:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oral Pomegranate Extract on the Microbiome and Skin Biophysical Properties

NCT04596722
View directory record Official record
Conditions
Human Microbiome
Interventions
Pomella, Placebo
Dietary Supplement · Other
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
25 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 19, 2026, 3:35 PM EDT
Completed Phase 2 Interventional Results available

A Study of Psilocybin for Major Depressive Disorder (MDD)

NCT03866174
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Psilocybin, Niacin, Set and Setting (SaS) Protocol
Drug · Other
Lead sponsor
Usona Institute
Other
Eligibility
21 Years to 65 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
11
States / cities
San Francisco, California • Santa Monica, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 19, 2026, 3:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Safety, and Tolerability of SYN-020

NCT04815993
View directory record Official record
Conditions
Enteritis Caused by Radiation (Disorder)
Interventions
SYN-020 delayed release capsule
Drug
Lead sponsor
Theriva Biologics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 19, 2026, 3:35 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients

NCT04603924
View directory record Official record
Conditions
COVID-19
Interventions
Niclosamide, Placebo
Drug
Lead sponsor
NeuroBo Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Sheffield, Alabama • Irvine, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 19, 2026, 3:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effect Study in Healthy Volunteers

NCT07254286
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Icovamenib, Icovamenib HPMC
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 19, 2026, 3:35 PM EDT
Active, not recruiting Phase 3 Interventional

Psilocybin for Major Depressive Disorder (MDD)

NCT06308653
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Psilocybin 25 mg, Inactive Placebo, Psilocybin 5 mg, Psychosocial Support
Drug · Behavioral
Lead sponsor
Usona Institute
Other
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
29
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 19, 2026, 3:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Single and Multiple Ascending Dose Study of Niclosamide in Healthy Volunteers

NCT04705415
View directory record Official record
Conditions
Healthy
Interventions
Niclosamide, Placebo
Drug
Lead sponsor
NeuroBo Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 19, 2026, 3:35 PM EDT
Recruiting Phase 2Phase 3 Interventional

Psilocybin Therapy in Advanced Cancer

NCT05398484
View directory record Official record
Conditions
Advanced Cancer
Interventions
Psilocybin 25 mgs, Niacin 100mg, Psychotherapy
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Aurora, Colorado • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 19, 2026, 3:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects

NCT05735249
View directory record Official record
Conditions
Healthy Adult Participants
Interventions
ARN-75039 oral capsules, Placebo
Drug
Lead sponsor
Arisan Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 19, 2026, 3:35 PM EDT